Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons.
Francesco ReggianiMatteo StellaMarta CalatroniRenato Alberto SinicoPublished in: Expert review of clinical immunology (2024)
There is hope that the new treatment targets currently under study in AAV may enable a faster and more lasting clinical response, ensuring the reduction of possible side effects from therapies. Moreover, numerous aspects necessitate further exploration in the future, such as tailoring of GCs, integration of GCs-sparing agents, efficacy of combination therapy, optimal maintenance therapy, to reduce organ-damage and improve quality of life.